ALGS News and Press, Aligos Therapeutics Inc. From 06/28/21

SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. In addition, Aligos intends to grant the underwriters a 30-day option to purchas...

- First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients -Presentations include nonclinical data from 3 other CHB programs SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therape...

-Five scientific posters to be presented at upcoming EASL ILC meeting - All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being evaluated in CHB subjects - ASO and siRNA drug candidates are on track to e...

membio/iStock via Getty Images Aligos Therapeutics ([[ALGS]] +5.8%) announced the data from a Phase 1 study evaluating ALG-000184 in healthy volunteers and patients with chronic Hepatitis B ((CHB)) who are not currently treated or who did not respond to previous treatments. Results ...

Subjects experienced a 2.9 log 10 IU/mL mean reduction in HBV DNA levels after 14 days’ dosing with 100 mg ALG-000184 Half (4 out of 8) of these subjects had HBV DNA levels below the lower limit of quantitation (LLOQ) on Day 14 SOUTH SAN FRANCISCO, Calif...

SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence Blatt, Ph.D.,...

Aligos Therapeutics (ALGS): Q1 GAAP EPS of -$0.74 beats by $0.16.Cash, cash equivalents and marketable securities totaled $213.4 million as of March 31, 2021 compared with $243.5 million as of December 31, 2020.Press release. For further details see: Aligos Therapeutics EPS beats by $0....

SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and...

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the com...

SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appo...